Literature DB >> 1748818

Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo.

R Harning1, J Cui, J C Bystryn.   

Abstract

Patients with vitiligo often have antibodies to pigment cells. To examine whether there is a relation between the presence of such antibodies and disease activity, sera of 24 patients with vitiligo (10 with active and 14 with inactive disease) and 19 normal individuals were tested for antibodies to pigment cell surface antigens using a live cell enzyme-linked immunoabsorbent assay. IgG pigment cell antibodies were present in 80% (eight of 10) of patients with active vitiligo but in none of those with inactive disease or in normal individuals. The antibody level of patients with active vitiligo (mean binding index [BI] 3.3 +/- 0.59) was significantly higher than in patients with inactive disease (BI 0.96 +/- 0.04) or normal individuals (BI 1.0 +/- 0.04, p less than 0.001). Antibodies present in eight patients with high titers of pigment cell antibodies reacted to three of four pigment cells but to only one of six unrelated cells. These findings indicate that a correlation exists between the incidence and level of pigment cell antibodies and the activity of vitiligo, and support the hypothesis that vitiligo is an autoimmune disease mediated by an immune reaction to pigment cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748818     DOI: 10.1111/1523-1747.ep12492607

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  26 in total

1.  Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo.

Authors:  E H Kemp; E A Waterman; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

3.  Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.

Authors:  I C Le Poole; R M van den Wijngaard; W Westerhof; P K Das
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 4.  Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments.

Authors:  Torello Lotti; Matteo Zanardelli; Angelo Massimiliano D'Erme
Journal:  Wien Med Wochenschr       Date:  2014-07-25

5.  Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients.

Authors:  Yulong Li; Min Yang; Rui Zhang; Wan Liu; Kuo Zhang; Wei Wen; Lang Yi; Qiaoxian Wang; Mingju Hao; Hui Yang; Jianmin Chang; Jinming Li
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

Review 6.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

7.  A Case of Vitiligo after Kawasaki's Disease.

Authors:  Han Kyoung Cho; Lucy Youngmin Eun; Ji-Sun Song; Won Hyoung Kang; Byung In Ro
Journal:  Ann Dermatol       Date:  2009-02-28       Impact factor: 1.444

8.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

9.  Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.

Authors:  O Merimsky; Y Shoenfeld; G Yecheskel; S Chaitchik; E Azizi; P Fishman
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

10.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.